Clinical Trial Imaging Market by Software & Services (Operational Imaging, Read Analysis), Modality (CT, MRI, X-ray, PET, Ultrasound, ECHO), Therapeutic Areas (Infectious, Oncology, CNS, CVS), End User (Pharma, Biotechnology, CRO) - Global Forecasts to 2026
The global clinical trial imaging market in terms of revenue was estimated to be worth $1.0 billion in 2021 and is poised to reach $1.4 billion by 2026, growing at a CAGR of 7.6% from 2021 to 2026. Market growth is driven by an increase in R&D spending, growth in the pharmaceutical and biotechnology industries, and an increasing number of CROs.
To know about the assumptions considered for the study, Request for Free Sample Report
Clinical Trial Imaging Market Dynamics
Drivers: Increase in R&D spending
Pharmaceutical and biotechnology companies invest heavily in research to develop breakthrough molecules. Growth in the R&D expenditure by pharmaceutical & biotechnology companies and governments, coupled with the increasing focus on life science projects to develop new therapeutic & diagnostic products, is expected to aid the clinical trial imaging market.
Opportunities: Developing Countries
Developing countries such as India, South Korea, Brazil, and Mexico offer significant growth opportunities to players operating in the global market, mainly due to the growing R&D funding in these countries. These developing markets also have a strong trend toward the commercialization of life science research. With significant developments in life sciences research, these economies are expected to offer high growth opportunities in the market.
Furthermore, Asian markets, especially China and India, have many CROs that offer drug discovery services to pharmaceutical and biotechnology companies. With the significant increase in R&D funding and CROs operating in emerging countries, the demand for clinical trial imaging is expected to increase in these countries in the coming years.
Restraint: High implementation cost of imaging systems
In the healthcare industry, there is a significant focus on reducing growing healthcare costs; most industry stakeholders are undertaking various initiatives to make this possible. It is difficult for imaging service providers to allocate significant capital for procuring high-cost equipment such as advanced radiology and other imaging systems in such a scenario. The cost of implementing an imaging system includes costs related to procuring, housing, and maintaining equipment. These high upfront costs, coupled with maintenance costs, tend to impact market growth negatively. To make optimal use of such equipment, imaging service providers need to hire experts such as experienced radiologists. Due to these factors, the implementation cost of imaging systems is very high, which is a major factor restraining the growth of the clinical trial imaging market.
Challenge: High cost of the clinical trial
Any research related to the advancement of healthcare includes clinical trials. Clinical trials are an essential part of documenting the effectiveness of innovations, whether for therapy, drugs, medical devices, diagnosis, or academic research. While laboratory experiments attempt to simulate the conditions of the human body, validating the efficacy and safety of drugs in the population of interest remains a necessary step. However, conducting a clinical trial to document the effect of a drug/therapy and monitor its side effects is a very expensive process.
Services segment accounted for the largest share of the clinical trial imaging market, by product and services
The market is segmented into services and software based on products and services. The services segment accounted for the largest share of the market in 2020, mainly due to the increase in R&D spending and growth in the pharmaceutical and biotechnology industries.
Computed tomography segment accounted for the largest share of the clinical trial imaging market, by modality
The market is segmented into computed tomography, magnetic resonance imaging, ultrasound, positron emission tomography, X-ray, echocardiography, and other modalities based on modality. In 2020, the computed tomography segment accounted for the largest share. Factors such as the increasing number of CROs, an increase in R&D spending, and growth in the pharmaceutical and biotechnology industries drive this market.
Oncology segment accounted for the largest share of the clinical trial imaging market, by therapeutic area
The market is segmented based on therapeutic area into oncology, infectious diseases, neurology, CVS, endocrinology, immunological disorders, and other therapeutic areas. In 2020, the oncology segment accounted for the largest share. Factors such as an increase in R&D spending and growth in the pharmaceutical and biotechnology industries drive this market.
Pharmaceutical companies segment accounted for the largest share in the clinical trial imaging market, by end users
The market has been segmented based on end users into pharmaceutical companies, biotechnology companies, medical device manufacturers, contract research organizations, academic and government research institutes, and other end users. The pharmaceutical companies segment held the largest market share in 2020. Growth in pharmaceutical and biotechnology companies, an increasing number of CROs, and an increase in R&D spending are driving the growth of this segment.
North America is the largest regional market for clinical trial imaging market
The global market is segmented into five major regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. In 2020, North America accounted for the largest share of the global clinical trial imaging industry. The North American market's growth can be attributed to an increase in R&D spending, an increasing number of CROs, and growth in the pharmaceutical and biotechnology industries.
To know about the assumptions considered for the study, download the pdf brochure
Some key players in the clinical trial imaging market (2021- 2026)
- ICON plc. (Ireland)
- BioTelemetry, Inc. (US)
- Biomedical Systems Corporation (US)
- Medpace Holdings, Inc. (US)
Clinical Trial Imaging Market Report Scope
|
Report Metric |
Details |
|
Market Revenue in 2021 |
$1.0 billion |
|
Estimated Value by 2026 |
$1.4 billion |
|
Growth Rate |
Poised to grow at a CAGR of 7.6% |
|
Largest Share Segments |
|
|
Market Report Segmentation |
Product and service, modality, therapeutic area, end user, and region |
|
Growth Drivers |
|
| Growth Opportunities |
|
|
Geographies covered |
North America, Europe, APAC, MEA, and Latin America |
Clinical Trial Imaging Market Report Segmentation
By Product and Service
-
Services
- Operational Imaging Services
- Read Analysis Services
- System and Technical Support Services
- Trial Design & Consulting Services
- Software
By Modality
- Computed Tomography
- Magnetic Resonance Imaging
- Ultrasound
- Positron Emission Tomography
- X-ray
- Echocardiography
By Therapeutic area
- Oncology
- Infectious Diseases
- Neurology
- CVS
- Endocrinology
- Immunological Disorder
By End User
- Pharmaceutical Companies
- Biotechnology Companies
- Medical Device Manufacturer
- Contract Research Organizations
- Academic and Government Research Institutes
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
-
Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
- Latin America
- Middle East & Africa
Recent Developments
- In May 2021 IXICO Plc. (UK) signed a contract with biopharmaceutical client IXICO to provide neuroimaging services for a Phase III clinical trial under this contract.
- In February 2021, ICON Plc. (Ireland) acquired PRA Health Science (US) to strengthen its global healthcare intelligence and clinical research business.
- In February 2021, Resonance Health Ltd. (Australia) received CE mark clearance for HepaFat AI software for commercialization in the European market.
Frequently Asked Questions (FAQs):
What is the size of Clinical Trial Imaging Market ?
The global clinical trial imaging market in terms of revenue was estimated to be worth $1.0 billion in 2021 and is poised to reach $1.4 billion by 2026, growing at a CAGR of 7.6% from 2021 to 2026
What are the major growth factors of Clinical Trial Imaging Market ?
Market growth is driven by increase in R&D spending, growth in pharmaceutical and biotechnology industries, increasing number of CROs.
Who all are the prominent players of Clinical Trial Imaging Market ?
The Clinical Trial Imaging Market is dominated by players such as ICON plc.(Ireland), BioTelemetry, Inc.(US), Biomedical Systems Corporation (US) and Medpace Holdings, Inc. (US) .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 33)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
1.2.2 MARKETS COVERED
FIGURE 1 CLINICAL TRIAL IMAGING MARKET SEGMENTATION
1.2.3 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 LIMITATIONS
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 37)
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 2 MARKET: RESEARCH DESIGN
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Key data from primary sources
2.2.2.2 Key industry insights
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
FIGURE 4 MARKET: BOTTOM-UP APPROACH
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH
FIGURE 6 MARKET: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.5 ASSUMPTIONS FOR THE STUDY
2.6 GROWTH RATE ASSUMPTIONS
2.7 LIMITATIONS
2.8 RISK ASSESSMENT
2.9 COVID-19 HEALTH ASSESSMENT
2.10 COVID-19 ECONOMIC ASSESSMENT
2.10.1 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
FIGURE 8 CRITERIA IMPACTING THE GLOBAL ECONOMY
FIGURE 9 RECOVERY SCENARIO OF THE GLOBAL ECONOMY
2.10.2 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE MARKET
3 EXECUTIVE SUMMARY (Page No. - 49)
FIGURE 10 CLINICAL TRIAL IMAGING MARKET, BY PRODUCT AND SERVICE, 2021 VS. 2026 (USD MILLION)
FIGURE 11 MARKET, BY MODALITY, 2021 VS. 2026 (USD MILLION)
FIGURE 12 MARKET, BY THERAPEUTIC AREA, 2021 VS. 2026 (USD MILLION)
FIGURE 13 MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
FIGURE 14 MARKET, BY REGION, 2021 VS. 2026 (USD MILLION)
4 PREMIUM INSIGHTS (Page No. - 53)
4.1 CLINICAL TRIAL IMAGING MARKET OVERVIEW
FIGURE 15 INCREASE IN R&D SPENDING TO DRIVE MARKET GROWTH
4.2 MARKET SHARE, BY PRODUCT & SERVICE, 2021 VS. 2026
FIGURE 16 SERVICES WILL CONTINUE TO DOMINATE THE MARKET IN 2026
4.3 MARKET SHARE, BY MODALITY, 2021 VS. 2026
FIGURE 17 COMPUTED TOMOGRAPHY TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
4.4 MARKET SHARE, BY THERAPEUTIC AREA, 2021 VS. 2026
FIGURE 18 ONCOLOGY IS THE LARGEST SEGMENT IN THE MARKET BY THERAPEUTIC AREA
4.5 MARKET SHARE, BY END USER, 2021 VS. 2026
FIGURE 19 PHARMACEUTICAL COMPANIES FORM THE LARGEST END USERS OF THE MARKET
4.6 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 20 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH RATE IN THE MARKET DURING THE FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 56)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 21 CLINICAL TRIAL IMAGING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing R&D spending
5.2.1.2 Growth in the pharmaceutical and biotechnology industries
5.2.1.3 Increasing number of CROs
5.2.2 RESTRAINTS
5.2.2.1 High implementation cost of imaging systems
5.2.3 OPPORTUNITIES
5.2.3.1 Developing countries
5.2.3.2 Development of innovative imaging modalities, contrast agents, molecular probes, and radiopharmaceuticals
5.2.4 CHALLENGES
5.2.4.1 High cost of clinical trials
5.3 IMPACT OF COVID-19 ON THE MARKET
5.4 PRICING ANALYSIS
TABLE 1 PRICES OF CLINICAL TRIAL IMAGING PRODUCTS (2021)
5.5 PATENT ANALYSIS
5.6 TRADE ANALYSIS
5.6.1 TRADE ANALYSIS FOR X-RAY APPARATUSES
TABLE 2 IMPORT DATA FOR X-RAY APPARATUSES, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 3 EXPORT DATA FOR X-RAY APPARATUSES, BY COUNTRY, 2016–2020 (USD MILLION)
5.6.2 TRADE ANALYSIS FOR CT APPARATUSES
TABLE 4 IMPORT DATA FOR CT APPARATUSES, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 5 EXPORT DATA FOR CT APPARATUSES, BY COUNTRY, 2016–2020 (USD MILLION)
5.7 VALUE CHAIN ANALYSIS
FIGURE 22 MAJOR VALUE IS ADDED DURING THE DEVELOPMENT AND PROCUREMENT PHASES
5.8 SUPPLY CHAIN ANALYSIS
FIGURE 23 DISTRIBUTION—A STRATEGY PREFERRED BY PROMINENT COMPANIES
5.9 ECOSYSTEM ANALYSIS OF THE GLOBAL MARKET
FIGURE 24 MARKET: ECOSYSTEM ANALYSIS
5.9.1 ROLE IN THE ECOSYSTEM
5.10 PORTER’S FIVE FORCES ANALYSIS
TABLE 6 GLBOAL MARKET: PORTER’S FIVE FORCES ANALYSIS
5.10.1 THREAT OF NEW ENTRANTS
5.10.2 THREAT OF SUBSTITUTES
5.10.3 BARGAINING POWER OF BUYERS
5.10.4 BARGAINING POWER OF SUPPLIERS
5.10.5 DEGREE OF COMPETITION
5.11 PESTLE ANALYSIS
5.12 REGULATORY LANDSCAPE
5.12.1 NORTH AMERICA
5.12.1.1 US
5.12.1.2 Canada
5.12.2 EUROPE
5.12.3 ASIA PACIFIC
5.12.3.1 Japan
5.12.3.2 India
5.12.3.3 China
5.12.4 LATIN AMERICA
5.12.4.1 Brazil
5.12.4.2 Mexico
5.12.5 MIDDLE EAST
5.12.6 AFRICA
5.13 TECHNOLOGY ANALYSIS
5.14 DISRUPTIVE TECHNOLOGIES IN THE MARKET
5.14.1 REVENUE SHIFT & REVENUE POCKETS FOR THE MARKET
FIGURE 25 REVENUE SHIFT FOR THE MARKET
6 CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE (Page No. - 71)
6.1 INTRODUCTION
TABLE 7 MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION)
TABLE 8 MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION)
6.2 SERVICES
TABLE 9 CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 10 CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 11 CLINICAL TRIAL IMAGING SERVICES MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 12 CLINICAL TRIAL IMAGING SERVICES MARKET, BY REGION, 2020–2026 (USD MILLION)
6.2.1 OPERATIONAL IMAGING SERVICES
6.2.1.1 The rising number of CROs supports the growth of this segment
FIGURE 26 INDUSTRY INSIGHTS ON OPERATIONAL IMAGING SERVICES
TABLE 13 OPERATIONAL IMAGING SERVICES MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 14 OPERATIONAL IMAGING SERVICES MARKET, BY REGION, 2020–2026 (USD MILLION)
6.2.2 READ ANALYSIS SERVICES
6.2.2.1 Increased number of clinical trials is the major factor supporting the growth of this segment
TABLE 15 READ ANALYSIS SERVICES MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 16 READ ANALYSIS SERVICES MARKET, BY REGION, 2020–2026 (USD MILLION)
6.2.3 SYSTEM & TECHNICAL SUPPORT SERVICES
6.2.3.1 Need for continuous technical support to drive this segment
TABLE 17 SYSTEM & TECHNICAL SUPPORT SERVICES MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 18 SYSTEM & TECHNICAL SUPPORT SERVICES MARKET, BY REGION, 2020–2026 (USD MILLION)
6.2.4 TRIAL DESIGN & CONSULTING SERVICES
6.2.4.1 Rising R&D spending and support for clinical trials will prompt companies to outsource trial design processes
TABLE 19 TRIAL DESIGN & CONSULTING SERVICES MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 20 TRIAL DESIGN & CONSULTING SERVICES MARKET, BY REGION, 2020–2026 (USD MILLION)
6.3 SOFTWARE
6.3.1 HIGH EFFICIENCY AND COST-SAVING BENEFITS OF SOFTWARE SUPPORT ITS ADOPTION
TABLE 21 CLINICAL TRIAL IMAGING SOFTWARE MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 22 CLINICAL TRIAL IMAGING SOFTWARE MARKET, BY REGION, 2020–2026 (USD MILLION)
7 CLINICAL TRIAL IMAGING MARKET, BY MODALITY (Page No. - 80)
7.1 INTRODUCTION
TABLE 23 MARKET, BY MODALITY, 2016–2019 (USD MILLION)
TABLE 24 MARKET, BY MODALITY, 2020–2026 (USD MILLION)
7.2 COMPUTED TOMOGRAPHY
7.2.1 QUICK RESULTS AND NO VISIBLE SIDE-EFFECTS DRIVE THE ADOPTION OF CT
TABLE 25 GLOBAL MARKET FOR COMPUTED TOMOGRAPHY, BY REGION, 2016–2019 (USD MILLION)
TABLE 26 MARKET FOR COMPUTED TOMOGRAPHY, BY REGION, 2020–2026 (USD MILLION)
7.3 MAGNETIC RESONANCE IMAGING
7.3.1 INCREASING ADOPTION OF MRI IN ONCOLOGICAL TRIALS AND STUDIES TO DRIVE MARKET GROWTH
TABLE 27 MARKET FOR MAGNETIC RESONANCE IMAGING, BY REGION, 2016–2019 (USD MILLION)
TABLE 28 MARKET FOR MAGNETIC RESONANCE IMAGING, BY REGION, 2020–2026 (USD MILLION)
7.4 ULTRASOUND
7.4.1 ULTRASOUND IMAGING IS SAFER THAN CT AND MRI IMAGING
TABLE 29 MARKET FOR ULTRASOUND, BY REGION, 2016–2019 (USD MILLION)
TABLE 30 MARKET FOR ULTRASOUND, BY REGION, 2020–2026 (USD MILLION)
7.5 POSITRON EMISSION TOMOGRAPHY
7.5.1 PET IS A PART OF NUCLEAR MEDICINE IMAGING
TABLE 31 MARKET FOR PET, BY REGION, 2016–2019 (USD MILLION)
TABLE 32 MARKET FOR PET, BY REGION, 2020–2026 (USD MILLION)
7.6 X-RAY
7.6.1 X-RAY IS MOST COMMONLY USED IN BONE, CHEST, AND DENTAL IMAGING
TABLE 33 MARKET FOR X-RAY, BY REGION, 2016–2019 (USD MILLION)
TABLE 34 MARKET FOR X-RAY, BY REGION, 2020–2026 (USD MILLION)
7.7 ECHOCARDIOGRAPHY
7.7.1 ECHO-DOPPLER PARAMETERS ARE CONSIDERED ACCEPTABLE AS A PROOF OF CONCEPT OF TREATMENT IN PHASE-II TRIALS
TABLE 35 MARKET FOR ECHOCARDIOGRAPHY, BY REGION, 2016–2019 (USD MILLION)
TABLE 36 MARKET FOR ECHOCARDIOGRAPHY, BY REGION, 2020–2026 (USD MILLION)
7.8 OTHER MODALITIES
TABLE 37 MARKET FOR OTHER MODALITIES, BY REGION, 2016–2019 (USD MILLION)
TABLE 38 MARKET FOR OTHER MODALITIES, BY REGION, 2020–2026 (USD MILLION)
8 CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA (Page No. - 91)
8.1 INTRODUCTION
TABLE 39 MARKET, BY THERAPEUTIC AREA, 2016–2019 (USD MILLION)
TABLE 40 MARKET, BY THERAPEUTIC AREA, 2016–2019 (USD MILLION)
TABLE 42 MARKET FOR ONCOLOGY, BY REGION, 2020–2026 (USD MILLION)
8.3 INFECTIOUS DISEASES
8.3.1 RISING DRUG DISCOVERY ACTIVITY SUPPORTS MARKET GROWTH
TABLE 43 MARKET FOR INFECTIOUS DISEASES, BY REGION, 2016–2019 (USD MILLION)
TABLE 44 MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020–2026 (USD MILLION)
8.4 NEUROLOGY
8.4.1 GROWING INVESTMENTS IN CNS DISORDER RESEARCH TO DRIVE SEGMENT GROWTH
TABLE 45 MARKET FOR NEUROLOGY, BY REGION, 2016–2019 (USD MILLION)
TABLE 46 MARKET FOR NEUROLOGY, BY REGION, 2020–2026 (USD MILLION)
8.5 CARDIOVASCULAR SYSTEM DISORDERS
8.5.1 HIGH MORTALITY RATE OF CVD HAS DRIVEN FOCUS ON THERAPEUTICS AND CLINICAL TRIALS
TABLE 47 MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2016–2019 (USD MILLION)
TABLE 48 MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2020–2026 (USD MILLION)
8.6 ENDOCRINOLOGY
8.6.1 RISING INCIDENCE OF DIABETES TO DRIVE MARKET GROWTH
TABLE 49 MARKET FOR ENDOCRINOLOGY, BY REGION, 2016–2019 (USD MILLION)
TABLE 50 MARKET FOR ENDOCRINOLOGY, BY REGION, 2020–2026 (USD MILLION)
8.7 IMMUNOLOGICAL DISORDERS
8.7.1 ALLERGIES, ASTHMA, AND AUTOIMMUNE DISEASES ARE HIGHLY COMMON AILMENTS GLOBALLY
TABLE 51 MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2016–2019 (USD MILLION)
TABLE 52 MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2020–2026 (USD MILLION)
8.8 OTHER THERAPEUTIC AREAS
TABLE 53 MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2016–2019 (USD MILLION)
TABLE 54 MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2020–2026 (USD MILLION)
9 CLINICAL TRIAL IMAGING MARKET, BY END USER (Page No. - 102)
9.1 INTRODUCTION
TABLE 55 MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 56 MARKET, BY END USER, 2020–2026 (USD MILLION)
9.2 PHARMACEUTICAL COMPANIES
9.2.1 INCREASING R&D ACTIVITIES BY PHARMACEUTICAL COMPANIES TO DRIVE MARKET GROWTH FOR THIS SEGMENT
TABLE 57 MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2016–2019 (USD MILLION)
TABLE 58 MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2020–2026 (USD MILLION)
9.3 BIOTECHNOLOGY COMPANIES
9.3.1 RISING R&D BUDGETS OF BIOTECH COMPANIES TO DRIVE GROWTH
TABLE 59 TOP BIOTECHNOLOGY INVESTMENT DEALS, 2019–2020
TABLE 60 MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2016–2019 (USD MILLION)
TABLE 61 MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2026 (USD MILLION)
9.4 MEDICAL DEVICE MANUFACTURERS
9.4.1 INCREASING R&D SPENDING BY MEDICAL DEVICES MANUFACTURERS TO DRIVE MARKET GROWTH
TABLE 62 MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY REGION, 2016–2019 (USD MILLION)
TABLE 63 MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY REGION, 2020–2026 (USD MILLION)
9.5 CONTRACT RESEARCH ORGANIZATIONS
9.5.1 INCREASING TREND OF OUTSOURCING TO DRIVE MARKET GROWTH
TABLE 64 MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2016–2019 (USD MILLION)
TABLE 65 MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2020–2026 (USD MILLION)
9.6 ACADEMIC & GOVERNMENT RESEARCH INSTITUTES
9.6.1 INCREASING RESEARCH ACTIVITIES TO DRIVE MARKET GROWTH
TABLE 66 MARKET FOR ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2016–2019 (USD MILLION)
TABLE 67 MARKET FOR ACADEMIC & GOVERNMENT RESEARCH INSTITUTES MARKET, BY REGION, 2020–2026 (USD MILLION)
9.7 OTHER END USERS
TABLE 68 MARKET FOR OTHER END USERS, BY REGION, 2016–2019 (USD MILLION)
TABLE 69 MARKET FOR OTHER END USERS, BY REGION, 2020–2026 (USD MILLION)
10 CLINICAL TRIAL IMAGING MARKET, BY REGION (Page No. - 113)
10.1 INTRODUCTION
TABLE 70 MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 71 MARKET, BY REGION, 2020–2026 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 27 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET SNAPSHOT
TABLE 72 NORTH AMERICA: MARKET, BY COUNTRY, 2016–2019 (USD MILLION)
TABLE 73 NORTH AMERICA: MARKET, BY COUNTRY, 2020–2026 (USD MILLION)
TABLE 74 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION)
TABLE 75 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION)
TABLE 76 NORTH AMERICA: MARKET, BY MODALITY, 2016–2019 (USD MILLION)
TABLE 77 NORTH AMERICA: MARKET, BY MODALITY, 2020–2026 (USD MILLION)
TABLE 78 NORTH AMERICA: MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 79 NORTH AMERICA: MARKET, BY END USER, 2020–2026 (USD MILLION)
10.2.1 US
10.2.1.1 Increased investment in the biopharmaceutical industry in the US to favor market growth
TABLE 80 US: PRODUCT APPROVALS IN THE CLINICAL TRIAL IMAGING SPACE
TABLE 81 US: MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION)
TABLE 82 US: MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION)
TABLE 83 US: MARKET, BY MODALITY, 2016–2019 (USD MILLION)
TABLE 84 US: MARKET, BY MODALITY, 2020–2026 (USD MILLION)
TABLE 85 US: MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 86 US: MARKET, BY END USER, 2020–2026 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Increase in per capita healthcare spending to drive the market in Canada
TABLE 87 CANADA: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION)
TABLE 88 CANADA: MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION)
TABLE 89 CANADA: MARKET, BY MODALITY, 2016–2019 (USD MILLION)
TABLE 90 CANADA: MARKET, BY MODALITY, 2020–2026 (USD MILLION)
TABLE 91 CANADA: MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 92 CANADA: MARKET, BY END USER, 2020–2026 (USD MILLION)
10.3 EUROPE
TABLE 93 EUROPE: MARKET, BY COUNTRY, 2016–2019 (USD MILLION)
TABLE 94 EUROPE: MARKET, BY COUNTRY, 2020–2026 (USD MILLION)
TABLE 95 EUROPE: MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION)
TABLE 96 EUROPE: MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION)
TABLE 97 EUROPE: MARKET, BY MODALITY, 2016–2019 (USD MILLION)
TABLE 98 EUROPE: MARKET, BY MODALITY, 2020–2026 (USD MILLION)
TABLE 99 EUROPE: MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 100 EUROPE: MARKET, BY END USER, 2020–2026 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Germany is the largest & fastest-growing market for clinical trial imaging in Europe
TABLE 101 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION)
TABLE 102 GERMANY: MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION)
TABLE 103 GERMANY: MARKET, BY MODALITY, 2016–2019 (USD MILLION)
TABLE 104 GERMANY: MARKET, BY MODALITY, 2020–2026 (USD MILLION)
TABLE 105 GERMANY: MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 106 GERMANY: MARKET, BY END USER, 2020–2026 (USD MILLION)
10.3.2 UK
10.3.2.1 Rising research investments to drive the market growth in the UK
TABLE 107 UK: MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION)
TABLE 108 UK: MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION)
TABLE 109 UK: MARKET, BY MODALITY, 2016–2019 (USD MILLION)
TABLE 110 UK: MARKET, BY MODALITY, 2020–2026 (USD MILLION)
TABLE 111 UK: MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 112 UK: MARKET, BY END USER, 2020–2026 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Rising R&D expenditure to drive market growth in France
TABLE 113 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION)
TABLE 114 FRANCE: MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION)
TABLE 115 FRANCE: MARKET, BY MODALITY, 2016–2019 (USD MILLION)
TABLE 116 FRANCE: MARKET, BY MODALITY, 2020–2026 (USD MILLION)
TABLE 117 FRANCE: MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 118 FRANCE: MARKET, BY END USER, 2020–2026 (USD MILLION)
10.3.4 ITALY
10.3.4.1 Increase R&D spending on healthcare to drive market growth in this region
TABLE 119 ITALY: MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION)
TABLE 120 ITALY: MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION)
TABLE 121 ITALY: MARKET, BY MODALITY, 2016–2019 (USD MILLION)
TABLE 122 ITALY: MARKET, BY MODALITY, 2020–2026 (USD MILLION)
TABLE 123 ITALY: MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 124 ITALY: MARKET, BY END USER, 2020–2026 (USD MILLION)
10.3.5 SPAIN
10.3.5.1 Growth of pharmaceutical companies
TABLE 125 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION)
TABLE 126 SPAIN: MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION)
TABLE 127 SPAIN: MARKET, BY MODALITY, 2016–2019 (USD MILLION)
TABLE 128 SPAIN: MARKET, BY MODALITY, 2020–2026 (USD MILLION)
TABLE 129 SPAIN: MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 130 SPAIN: MARKET, BY END USER, 2020–2026 (USD MILLION)
10.3.6 REST OF EUROPE
TABLE 131 ROE: MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION)
TABLE 132 ROE: MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION)
TABLE 133 ROE: MARKET, BY MODALITY, 2016–2019 (USD MILLION)
TABLE 134 ROE: MARKET, BY MODALITY, 2020–2026 (USD MILLION)
TABLE 135 ROE: MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 136 ROE: MARKET, BY END USER, 2020–2026 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 28 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET SNAPSHOT
TABLE 137 ASIA PACIFIC: MARKET, BY COUNTRY, 2016–2019 (USD MILLION)
TABLE 138 ASIA PACIFIC: MARKET, BY COUNTRY, 2020–2026 (USD MILLION)
TABLE 139 ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION)
TABLE 140 ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION)
TABLE 141 ASIA PACIFIC: MARKET, BY MODALITY, 2016–2019 (USD MILLION)
TABLE 142 ASIA PACIFIC: MARKET, BY MODALITY, 2020–2026 (USD MILLION)
TABLE 143 ASIA PACIFIC: MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 144 ASIA PACIFIC: MARKET, BY END USER, 2020–2026 (USD MILLION)
10.4.1 CHINA
10.4.1.1 Increase in research spending to drive market growth
TABLE 145 CHINA: KEY MACROINDICATORS
TABLE 146 CHINA: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION)
TABLE 147 CHINA: MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION)
TABLE 148 CHINA: MARKET, BY MODALITY, 2016–2019 (USD MILLION)
TABLE 149 CHINA: MARKET, BY MODALITY, 2020–2026 (USD MILLION)
TABLE 150 CHINA: MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 151 CHINA: MARKET, BY END USER, 2020–2026 (USD MILLION)
10.4.2 JAPAN
10.4.2.1 Rising population and healthcare expenditure are favorable factors in Japan
TABLE 152 JAPAN: KEY MACROINDICATORS
TABLE 153 JAPAN: MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION)
TABLE 154 JAPAN: MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION)
TABLE 155 JAPAN: MARKET, BY MODALITY, 2016–2019 (USD MILLION)
TABLE 156 JAPAN: MARKET, BY MODALITY, 2020–2026 (USD MILLION)
TABLE 157 JAPAN: MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 158 JAPAN: MARKET, BY END USER, 2020–2026 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Increased investment in R&D to drive the adoption of clinical trial imaging
TABLE 159 INDIA: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION)
TABLE 160 INDIA: MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION)
TABLE 161 INDIA: MARKET, BY MODALITY, 2016–2019 (USD MILLION)
TABLE 162 INDIA: MARKET, BY MODALITY, 2020–2026 (USD MILLION)
TABLE 163 INDIA: MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 164 INDIA: MARKET, BY END USER, 2020–2026 (USD MILLION)
10.4.4 REST OF ASIA PACIFIC
TABLE 165 ROAPAC: MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION)
TABLE 166 ROAPAC: MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION)
TABLE 167 ROAPAC: MARKET, BY MODALITY, 2016–2019 (USD MILLION)
TABLE 168 ROAPAC: MARKET, BY MODALITY, 2020–2026 (USD MILLION)
TABLE 169 ROAPAC: MARKET, BY END USER , 2016–2019 (USD MILLION)
TABLE 170 ROAPAC: MARKET, BY END USER, 2020–2026 (USD MILLION)
10.5 LATIN AMERICA
10.5.1 INCREASING R&D DUE TO DISEASE OUTBREAKS TO SUPPORT MARKET GROWTH
TABLE 171 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION)
TABLE 172 LATIN AMERICA: MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION)
TABLE 173 LATIN AMERICA: MARKET, BY MODALITY, 2016–2019 (USD MILLION)
TABLE 174 LATIN AMERICA: MARKET, BY MODALITY, 2020–2026 (USD MILLION)
TABLE 175 LATIN AMERICA: MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 176 LATIN AMERICA: MARKET, BY END USER, 2020–2026 (USD MILLION)
10.6 MIDDLE EAST & AFRICA
10.6.1 INCREASED FUNDING AND PARTNERSHIPS IN THE RESEARCH SECTOR TO PROPEL MARKET GROWTH
TABLE 177 MIDDLE EAST & AFRICA: MARKET, BY PRODUCT & SERVICE, 2016–2019 (USD MILLION)
TABLE 178 MIDDLE EAST AND AFRICA: MARKET, BY PRODUCT & SERVICE, 2020–2026 (USD MILLION)
TABLE 179 MIDDLE EAST & AFRICA: MARKET, BY MODALITY, 2016–2019 (USD MILLION)
TABLE 180 MIDDLE EAST & AFRICA: MARKET, BY MODALITY, 2020–2026 (USD MILLION)
TABLE 181 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2016–2019 (USD MILLION)
TABLE 182 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2020–2026 (USD MILLION)
11 COMPETITIVE LANDSCAPE (Page No. - 163)
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
11.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN THE MARKET
TABLE 183 OVERVIEW OF STRATEGIES DEPLOYED BY KEY CLINICAL TRIAL IMAGING PRODUCT MANUFACTURING COMPANIES
11.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS
FIGURE 29 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE MARKET
11.4 MARKET SHARE ANALYSIS
FIGURE 30 MARKET SHARE, BY KEY PLAYER (2020)
TABLE 184 MARKET: DEGREE OF COMPETITION
11.5 COMPANY EVALUATION QUADRANT
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
FIGURE 31 MARKET: COMPANY EVALUATION QUADRANT, 2020
11.6 COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES (2020)
11.6.1 PROGRESSIVE COMPANIES
11.6.2 STARTING BLOCKS
11.6.3 RESPONSIVE COMPANIES
11.6.4 DYNAMIC COMPANIES
FIGURE 32 MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2020
11.7 COMPETITIVE BENCHMARKING
FIGURE 33 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF THE TOP PLAYERS IN THE MARKET
TABLE 185 COMPANY PRODUCT FOOTPRINT
TABLE 186 COMPANY GEOGRAPHICAL FOOTPRINT
11.8 COMPETITIVE SCENARIO
11.8.1 PRODUCT LAUNCHES & REGULATORY APPROVALS
TABLE 187 KEY PRODUCT LAUNCHES & REGULATORY APPROVALS
11.8.2 DEALS
TABLE 188 KEY DEALS
12 COMPANY PROFILES (Page No. - 172)
12.1 KEY PLAYERS
(Business Overview, Products and Services Offered, Recent Developments, MnM View, Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats)*
12.1.1 ICON PLC.
TABLE 189 ICON PLC.: BUSINESS OVERVIEW
FIGURE 34 ICON PLC.: COMPANY SNAPSHOT (2020)
12.1.2 BIOTELEMETRY INC.
TABLE 190 BIOTELEMETRY INC.: BUSINESS OVERVIEW
FIGURE 35 PHILIPS GROUP: COMPANY SNAPSHOT (2020)
12.1.3 BIOMEDICAL SYSTEMS CORPORATION (A PART OF ERT CLINICAL)
TABLE 191 BIOMEDICAL SYSTEMS CORPORATION: BUSINESS OVERVIEW
12.1.4 MEDPACE HOLDINGS INC.
TABLE 192 MEDPACE HOLDINGS INC.: BUSINESS OVERVIEW
FIGURE 36 MEDPACE HOLDINGS INC.: COMPANY SNAPSHOT (2020)
12.1.5 IXICO PLC.
TABLE 193 IXICO PLC.: BUSINESS OVERVIEW
FIGURE 37 IXICO PLC.: COMPANY SNAPSHOT (2020)
12.1.6 RESONANCE HEALTH LTD.
TABLE 194 RESONANCE HEALTH LTD.: BUSINESS OVERVIEW
FIGURE 38 RESONANCE HEALTH LTD.: COMPANY SNAPSHOT (2020)
12.1.7 RADIANT SAGE
TABLE 195 RADIANT SAGE: BUSINESS OVERVIEW
12.1.8 BIOCLINICA INC.
TABLE 196 BIOCLINICA: BUSINESS OVERVIEW
12.1.9 INTRINSIC IMAGING
TABLE 197 INTRINSIC IMAGING: BUSINESS OVERVIEW
12.1.10 CARDIOVASCULAR IMAGING TECHNOLOGIES
TABLE 198 CARDIOVASCULAR IMAGING TECHNOLOGIES: BUSINESS OVERVIEW
12.2 OTHER PLAYERS
12.2.1 MEDICAL METRICS
12.2.2 PRISM CLINICAL IMAGING
12.2.3 BOSTON IMAGING CORE LAB
12.2.4 ANAGRAM 4 CLINICAL TRIALS
12.2.5 LYSCAUT MEDICAL IMAGING COMPANY
12.2.6 CALYX GROUP
12.2.7 BIOSPECTIVE
12.2.8 PROSCAN IMAGING
12.2.9 MICRON
12.2.10 IMAGING ENDPOINTS LI LLC.
12.2.11 PERSPECTUM
12.2.12 PHARMTRACE KLINISCHE ENTWICKLUNG
12.2.13 WORLDCARE CLINICAL
*Details on Business Overview, Products and Services Offered, Recent Developments, MnM View, Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats might not be captured in case of unlisted companies.
13 APPENDIX (Page No. - 198)
13.1 INDUSTRY INSIGHTS
13.2 DISCUSSION GUIDE
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.4 AVAILABLE CUSTOMIZATIONS
13.5 RELATED REPORTS
13.6 AUTHOR DETAILS
This study involved four major activities in estimating the current size of the clinical trial imaging market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate segments and subsegments' market size.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the clinical trial imaging market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry have been identified through extensive secondary research
- The revenues generated by leading players operating in the global market have been determined through primary and secondary research
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
Global Clinical Trial Imaging Market Size: Top-Down Approach
To know about the assumptions considered for the study, download the pdf brochure
Data Triangulation
After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Report Objectives
- To define, describe, segment, and forecast the clinical trial imaging market by product & service, modality, therapeutic area, end user, and region.
- To provide detailed information regarding the major factors influencing the market growth (drivers, restraints, opportunities, and challenges).
- To analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall market.
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players.
- To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa,
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies2.
- To track and analyze company developments such as acquisitions, agreements, partnerships, contracts, approvals, product launches, and mergers in the global market.
- To benchmark players within the market using the proprietary “Competitive Leadership Mapping” framework, which analyzes market players on various parameters within the broad categories of business and product strategy.
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Country Information
- Clinical trial imaging market size and growth rate estimates for countries in the Rest of Europe, the Rest of Asia Pacific, Latin America, and Middle East & Africa.
Company profiles
- Product portfolio matrix for leading market players.
Growth opportunities and latent adjacency in Clinical Trial Imaging Market
Decode Al development designed nano human anology of all engineering military weaponry development